AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie Inc.’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

Pharmaceutical giant AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...

As with many other companies AbbVie Inc. (NYSE:ABBV) makes use of debt. But should shareholders be worried about its use of debt? Debt is a tool to help businesses grow, but if a business is incapable ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The FDA has scolded AbbVie for making false and misleading claims about a TV ad about a migraine pill that features Serena ...

AbbVie's longtime CEO, Richard Gonzalez, who held his position since the business spun off from Abbott Laboratories in 2013, ...

UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its ...